Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Published byIvan Tanudjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse."— Presentation transcript:

1 Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages.
Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. (A) Impact of Bio-AMS on viability of Mtb in standard liquid culture. The dashed line indicates the limit of detection. The frontline anti-TB drug isoniazid was used as a control. (B) Impact of Bio-AMS on growth of Mtb cultured on different carbon sources. Relative growth was calculated by dividing OD580 (optical density at 580 nm) of the culture treated with Bio-AMS by the OD580 of the culture in the absence of Bio-AMS. (C) Impact of Bio-AMS on intracellular Mtb in mouse macrophages. Mouse bone marrow–derived macrophages were infected with Mtb in vitro, and the culture was treated with Bio-AMS or dimethyl sulfoxide (DMSO) vehicle 24 hours after infection. Data are representative of two independent experiments each with three replicates and are means ± SEM (**P < 0.01, Student’s t test). Divya Tiwari et al., Sci Transl Med 2018;10:eaal1803 Published by AAAS

Download ppt "Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse."

Similar presentations

LTB4 production is elevated in preclinical and clinical lymphedema

LTB4 production is elevated in preclinical and clinical lymphedema
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.

Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition
BET inhibition and depletion repress the expression of BRCA1 and RAD51

BET inhibition and depletion repress the expression of BRCA1 and RAD51
Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.
Fig. 4. Functional annotation of VUS in EGFR.

Fig. 4. Functional annotation of VUS in EGFR.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.

Similar presentations

Ads by Google